| dc.contributor.author | Ng'ang'a, Zipporah W. | |
| dc.contributor.author | Nyamache, A. K. | |
| dc.contributor.author | Waihenya, R. | |
| dc.contributor.author | Muigai, A. W. | |
| dc.contributor.author | Khamadi, S. A. | |
| dc.date.accessioned | 2014-12-03T08:49:41Z | |
| dc.date.available | 2014-12-03T08:49:41Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | East Afr Med J. 2011 Jan;88(1):4-8. | en_US |
| dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/24968596 | |
| dc.identifier.uri | http://hdl.handle.net/123456789/303 | |
| dc.description.abstract | OBJECTIVE: To evaluate the extent of HIV-1 drug resistance among drug naive Kenyan individuals. DESIGN: Cross-sectional study. SETTING: Kenya Medical Research Institute HIV laboratory Nairobi, Kenya. SUBJECTS: A total of seventy eight HIV-1 positive drug naive subjects randomised from five Kenyan provincial hospitals between April and June 2004. RESULTS: A major non-nucleoside reverse transcriptase (NNRTI) an associated mutation was found in one patient (1.3%). NNRTI associated resistance mutations were present at amino acid codon sites G98A (2.56%); K103E (1.3%) and L100F (3.57%) prevalences. Baseline resistance may compromise the response to standard NNRTI-based first-line ART in 1.3 % of the study subjects. CONCLUSION: This indicates in general, that drug resistance among HIV-1 positive drug naive individual is at low thresholds (1.3%) but the problem could be more serious than reported here. Continuous resistance monitoring is therefore warranted to maintain individual and population-level ART effectiveness. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Kenya Medical Association | en_US |
| dc.title | Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans. | en_US |
| dc.type | Article | en_US |